ArticleTranslational andrology and urology2026
Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2025 at the 112
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Advanced Prostate Cancer Consensus Conference (APCCC) is a forum for discussing and debating current questions regarding the clinical management of patients with advanced prostate cancer, with a particular focus on these controversies. The aim of this study is to summarize and discuss the results of APCCC-JAPAN 2025 and APCCC 2024 to elucidate the current consensus for advanced prostate cancer in Japan. Methods: A total of 183 topics on advanced prostate cancer with substantial effects on daily practice but insufficient high-level evidence were addressed at APCCC 2024. From these, 16 questions were selected and presented by a panel of six prostate cancer experts at APCCC-JAPAN 2025 during the 112 Results: Differences in voting results were observed between APCCC-JAPAN 2025 and APCCC 2024, particularly regarding treatment strategies for localized high-risk prostate cancer and metastatic hormone-sensitive prostate cancer. Conclusions: The APCCC-JAPAN 2025 highlighted critical aspects of the current issues surrounding the management of advanced prostate cancer in Japan. Both similarities and differences were observed in the treatment approaches employed by Japanese urologists and global prostate cancer experts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.